In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BSD gets breast cancer therapy patent from Duke:

This article was originally published in Clinica

Executive Summary

BSD Medical has signed an exclusive patent licence agreement for rights to Duke University's hyperthermia treatment for primary breast cancer. The Salt Lake City, Utah-based firm intends to integrate the technology with its current BSD-2000 and BSD-500 hyperthermia systems. The treatment will be used to complement radiation therapy, chemotherapy and heat-released, targeted liposome drug delivery. BSD claims that the potential to treat breast cancer with hyperthermia therapy has been boosted by trials at the Durham, North Carolina university. Studies have shown that patients receiving radiation therapy in conjunction with hyperthermia have a greater chance of complete response compared with those receiving radiotherapy alone.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts